1. World Health Organization. The importance of pharmacovigilance—safety monitoring of medicinal products. WHO. 2002. https://www.apps.who.int/medicinedocs/en/d/Js4893e/. Accessed 24 Jan 2020.
2. World Health Organization. WHO Global Benchmarking Tool (GBT) for evaluation of national regulatory system of medical products, revision VI version 1. WHO. Nov 2018. https://www.who.int/medicines/areas/regulation/01_GBT_RS_RevVI.pdf. Accessed 24 Jan 2020.
3. The Global Fund, World Health Organization. Minimum requirements for a functional pharmacovigilance system. WHO. 2010. https://www.who.int/medicines/areas/quality_safety/safety_efficacy/PV_Minimum_Requirements_2010_2.pdf. Accessed 24 Jan 2020.
4. International Federation of Pharmaceutical Manufacturers & Associations. IFPMA Position Paper: Considerations for effective regulatory reliance—an Industry perspective. IFPMA. 2019. https://www.ifpma.org/resource-centre/ifpma-position-paper-on-regulatory-reliance/. Accessed 24 Jan 2020.
5. International Conference on Harmonisation of technical requirements for registration of pharmaceuticals for human use. E2D Post-approval safety data management: Note for guidance on definitions and standards for expedited reporting. ICH. 2003. https://www.ich.org/page/efficacy-guidelines. Accessed 24 Jan 2020.